David W Volk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6045463/publications.pdf

Version: 2024-02-01

41 papers 7,749 citations

147566 31 h-index 276539 41 g-index

43 all docs 43 docs citations

43 times ranked 6842 citing authors

#	Article	IF	CITATIONS
1	Involvement of the nuclear factor- \hat{l}^0B transcriptional complex in prefrontal cortex immune activation in bipolar disorder. Translational Psychiatry, 2021, 11, 40.	2.4	11
2	The Role of the Nuclear Factor-κB Transcriptional Complex in Cortical Immune Activation in Schizophrenia. Biological Psychiatry, 2019, 85, 25-34.	0.7	58
3	Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia. JAMA Psychiatry, 2019, 76, 887.	6.0	4
4	Altered brain cannabinoid 1 receptor mRNA expression across postnatal development in the MAM model of schizophrenia. Schizophrenia Research, 2018, 201, 254-260.	1.1	12
5	Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiology of Disease, 2017, 99, 58-65.	2.1	39
6	Altered Expression of ARP2/3 Complex Signaling Pathway Genes in Prefrontal Layer 3 Pyramidal Cells in Schizophrenia. American Journal of Psychiatry, 2017, 174, 163-171.	4.0	33
7	Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia. Schizophrenia Bulletin, 2016, 42, 396-405.	2.3	17
8	l-Proline, GABA Synthesis and Gamma Oscillations in Schizophrenia. Trends in Neurosciences, 2016, 39, 797-798.	4.2	8
9	Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia. Schizophrenia Research, 2016, 177, 3-9.	1.1	36
10	Dysregulated ErbB4 Splicing in Schizophrenia: Selective Effects on Parvalbumin Expression. American Journal of Psychiatry, 2016, 173, 60-68.	4.0	70
11	The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia. Biological Psychiatry, 2016, 79, 595-603.	0.7	53
12	Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia. American Journal of Psychiatry, 2015, 172, 1112-1121.	4.0	111
13	Chemokine receptors and cortical interneuron dysfunction in schizophrenia. Schizophrenia Research, 2015, 167, 12-17.	1.1	28
14	Altered Cortical Expression of GABA-Related Genes in Schizophrenia: Illness Progression vs Developmental Disturbance. Schizophrenia Bulletin, 2015, 41, 180-191.	2.3	117
15	Cortical Inhibitory Neuron Disturbances in Schizophrenia: Role of the Ontogenetic Transcription Factor Lhx6. Schizophrenia Bulletin, 2014, 40, 1053-1061.	2.3	22
16	Early Developmental Disturbances of Cortical Inhibitory Neurons: Contribution to Cognitive Deficits in Schizophrenia. Schizophrenia Bulletin, 2014, 40, 952-957.	2.3	76
17	Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophrenia Research, 2014, 159, 124-129.	1.1	52
18	Elevated Viral Restriction Factor Levels in Cortical Blood Vessels in Schizophrenia. Biological Psychiatry, 2014, 76, 160-167.	0.7	35

#	Article	IF	CITATIONS
19	Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience, 2013, 248, 154-164.	1.1	49
20	Endocannabinoid metabolism in the prefrontal cortex in schizophrenia. Schizophrenia Research, 2013, 147, 53-57.	1.1	32
21	Role of glutamic acid decarboxylase 67 in regulating cortical parvalbumin and GABA membrane transporter 1 expression: Implications for schizophrenia. Neurobiology of Disease, 2013, 50, 179-186.	2.1	52
22	Cortical Opioid Markers in Schizophrenia and across Postnatal Development. Cerebral Cortex, 2012, 22, 1215-1223.	1.6	43
23	Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends in Neurosciences, 2012, 35, 57-67.	4.2	892
24	Deficits in Transcriptional Regulators of Cortical Parvalbumin Neurons in Schizophrenia. American Journal of Psychiatry, 2012, 169, 1082-1091.	4.0	135
25	Cortical Glutamic Acid Decarboxylase 67 Deficiency Results in Lower Cannabinoid 1 Receptor Messenger RNA Expression: Implications for Schizophrenia. Biological Psychiatry, 2012, 71, 114-119.	0.7	19
26	Cortical Deficits of Glutamic Acid Decarboxylase 67 Expression in Schizophrenia: Clinical, Protein, and Cell Type-Specific Features. American Journal of Psychiatry, 2011, 168, 921-929.	4.0	237
27	Prefrontal Cortical Circuits in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 485-508.	0.8	90
28	Alterations in Metabotropic Glutamate Receptor $1\hat{l}\pm$ and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia. American Journal of Psychiatry, 2010, 167, 1489-1498.	4.0	117
29	Altered Markers of Tonic Inhibition in the Dorsolateral Prefrontal Cortex of Subjects With Schizophrenia. American Journal of Psychiatry, 2009, 166, 450-459.	4.0	77
30	Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Molecular Psychiatry, 2008, 13, 147-161.	4.1	447
31	Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience, 2005, 6, 312-324.	4.9	2,065
32	GABA Targets for the Treatment of Cognitive Dysfunction in Schizophrenia. Current Neuropharmacology, 2005, 3, 45-62.	1.4	33
33	Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology, 2004, 174, 143-50.	1.5	224
34	Effects of a mediodorsal thalamus lesion on prefrontal inhibitory circuitry: implications for schizophrenia. Biological Psychiatry, 2003, 53, 385-389.	0.7	23
35	Gene Expression Deficits in a Subclass of GABA Neurons in the Prefrontal Cortex of Subjects with Schizophrenia. Journal of Neuroscience, 2003, 23, 6315-6326.	1.7	843
36	Reciprocal Alterations in Pre- and Postsynaptic Inhibitory Markers at Chandelier Cell Inputs to Pyramidal Neurons in Schizophrenia. Cerebral Cortex, 2002, 12, 1063-1070.	1.6	244

#	Article	IF	CITATIONS
37	Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiology and Behavior, 2002, 77, 501-505.	1.0	149
38	GABA Transporter-1 mRNA in the Prefrontal Cortex in Schizophrenia: Decreased Expression in a Subset of Neurons. American Journal of Psychiatry, 2001, 158, 256-265.	4.0	202
39	Decreased Glutamic Acid Decarboxylase67 Messenger RNA Expression in a Subset of Prefrontal Cortical Î ³ -Aminobutyric Acid Neurons in Subjects With Schizophrenia. Archives of General Psychiatry, 2000, 57, 237.	13.8	622
40	Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biological Psychiatry, 1999, 46, 616-626.	0.7	252
41	Increased density of microtubule associated protein 2-immunoreactive neurons in the prefrontal white matter of schizophrenic subjects. Schizophrenia Research, 1996, 19, 111-119.	1.1	114